New data on four Bristol-Myers Squibb Company (NYSE: BMY) compounds will be presented at the 60th annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 30 to November 3.
Data will be presented on BARACLUDE(R) (entecavir) in patients with chronic hepatitis B, and on two compounds in early clinical development for the treatment of hepatitis C - BMS-650032, an NS3 inhibitor, and PEG-Interferon lambda, a novel type 3 interferon. The presentation of data on BMS-650032 will mark the first public disclosure of information about this investigational compound. Data will also be presented on the investigational compound brivanib, the first selective dual inhibitor of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) signaling, which is in Phase 3 development for the treatment of hepatocellular carcinoma.
"The data on Bristol-Myers Squibb compounds that will be presented at AASLD demonstrate the breadth of our research and development portfolio and support the company's goal of developing innovative medicines for patients with various diseases of the liver," said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, Research and Development, Bristol-Myers Squibb. "Our established expertise in viral hepatitis and oncology uniquely position Bristol-Myers Squibb to be at the forefront of delivering innovation in the treatment of multiple types and stages of liver disease. We are proud to be releasing new data on our significant portfolio of assets."
BARACLUDE, BMS-650032 and brivanib were discovered by Bristol-Myers Squibb Research and Development. BMS-650032 is Bristol-Myers Squibb's second small molecule under development for the treatment of hepatitis C, joining BMS-790052, a first-in-class investigational NS5A inhibitor of the hepatitis C virus.
PEG-Interferon lambda was discovered by ZymoGenetics, Inc. Bristol-Myers Squibb and ZymoGenetics announced a global collaboration for PEG-Interferon lambda and its related development program earlier this year.
The times, titles and lead authors of the data presentations are as follows:
| Date/Time | Presentation Title | Lead Author |
| Hepatitis B | ||
| October 31, | Efficacy and Safety of | Y. Liaw |
| 2:00 - 8:00 | Entecavir versus | Chang Gung |
| p.m. EDT | Adefovir in Chronic | Memorial Hospital, |
| Hepatitis B Patients | Chang Gung | |
| with Evidence of Hepatic | University College of Medicine | |
| Decompensation (Abstract #422) | Taipei, Taiwan | |
| Hepatitis C | ||
| November 3 | Safety, Tolerability, | C. Pasquinelli |
| 12:00 - 12:15 | Pharmacokinetics and | Bristol-Myers Squibb |
| p.m. EST | Antiviral Activity | |
| following Single- and Multiple-Dose | ||
| Administration of BMS-650032 a Novel | ||
| HCV NS3 Inhibitor in Subjects with Chronic | ||
| Genotype 1 HCV | ||
| Infection (Abstract #225) | ||
| November 3 | Genotypic and Phenotypic Analysis | F. McPhee |
| 8:00 a.m. | of Samples from HCV-Infected Subjects | Bristol-Myers Squibb |
| 1:00 p.m. EST | Treated with BMS-650032 in a Single Ascending Dose | |
| Study (Abstract #1607) | ||
| November 3 | A Phase 1b | A.J. Muir |
| 8:00 a.m. - | Dose-Ranging Study of | Duke University |
| 1:00 p.m. EST | 4 Weeks of | School of Medicine |
| PEG-Interferon (IFN) | Durham, North Carolina | |
| Lambda (PEG-rIL-29) | ||
| in Combination with Ribavirin (RBV) in Patients with Chronic Genotype 1 Hepatitis | ||
| C Virus (HCV) | ||
| Infection (Abstract #1591) | ||
| Hepatocellular Carcinoma | ||
| November 3 | Time-to-Progression | R. Finn |
| 8:00 a.m. - 1:00 p.m. EST | Analysis of Second-line Treatment with Brivanib in | UCLA Los Angeles, CA |
| Patients with Unresectable, Locally | ||
| Advanced, or Metastatic | ||
| Hepatocellular | ||
| Carcinoma (Abstract #1683) | ||
| November 3 | Cell-dependent | J. Park |
| 8:00 a.m. - 1:00 p.m. EST | Response of | National Cancer Center |
| BMS-582664 (Brivanib) | Goyang, South Korea | |
| in Hepatocellular | ||
| Carcinoma Cells: Gene | ||
| Expression Profiling | ||
| Study (Abstract #1668) |
About BARACLUDE(R)
Discovered at Bristol-Myers Squibb, BARACLUDE(R) is a nucleoside analogue indicated for use in adults with chronic hepatitis B infection with compensated liver disease, evidence of active viral replication, and either evidence of persistent elevations of the blood levels of aminotransferases - a marker for liver disease - or active liver disease as determined by biopsy.
BARACLUDE (entecavir) has been approved in more than 86 countries and regions around the world.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com.
BARACLUDE(R) (entecavir) is a registered trademark of Bristol-Myers Squibb Company.
Source: Bristol-Myers Squibb
Kontakt: Media, Annie Simond, office-tel.: +33-1-58-83-65-66, e-mail: annie.simond@bms.com, or Investors, John Elicker, tel.: +1-609-252-4611, e-mail: john.elicker@bms.com